CAR T Study For Blockbuster Drug Granted Breakthrough Therapy Designation For Multiple Myeloma
Source: Signant Health

A pharmaceutical sponsor needed help with a two-part, multisite Phase 1 study in adults with relapsed/refractory multiple myeloma. Specifically, the sponsor was looking for a team with CAR T experience, and a system that could handle their unique database built. In addition, the sponsor also required a team that could provide in-house data management, as well as a biostatistical team.
Discover how the company was able to overcome prior vendor relationship frustrations and receive support for a database build of EDC and IRT, as well as get aid with data management and biostatistics.
access the Case Study!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
Subscribe to Clinical Leader
X
Subscribe to Clinical Leader
Signant Health
This website uses cookies to ensure you get the best experience on our website. Learn more